Jade Biosciences to Participate in Upcoming Conferences

Jade Biosciences (JBIO) will participate in four healthcare conferences, beginning with Guggenheim’s Healthcare Innovation Conference on November 10, 2026.

Rhea-AI Summary

Jade Biosciences (JBIO) will participate in four healthcare conferences, beginning with Guggenheim’s Healthcare Innovation Conference on November 10, 2026.

Additional fireside chats are scheduled at Stifel on November 11, UBS on November 16 and Jefferies on November 17. Management will host one-on-one investor meetings. Live webcasts will be available on Jade’s Events page, with replays accessible for 90 days after each event.

Key Terms

cytokine, immunoglobulin a nephropathy, afucosylated, monoclonal antibody

4 terms

cytokine medical

"targets the cytokine APRIL"

Small proteins produced by cells that act as chemical messengers to coordinate immune and inflammatory responses, like text messages or traffic signals telling cells when to activate, calm down, or move. Investors care because cytokines are common drug targets and biomarkers; changes in cytokine activity can determine a therapy’s effectiveness, safety, regulatory approval, and market potential, so trial results or safety signals tied to cytokines often drive stock moves.

immunoglobulin a nephropathy medical

"treatment of immunoglobulin A nephropathy"

A kidney disease in which a specific antibody called IgA builds up in the kidney’s tiny filters, causing inflammation and gradual loss of filtering function — like grit clogging a coffee filter. It matters to investors because the condition can lead to long-term treatment needs (medications, monitoring, dialysis, transplants) and is the focus of drug trials and regulatory review, so progress or setbacks directly affect healthcare spending, company revenues and insurer liabilities.

afucosylated medical

"an afucosylated anti-BAFF-R monoclonal antibody"

Afucosylated describes a biologic drug—usually an antibody—that has had a specific sugar molecule (fucose) removed from its tail region, which changes how well immune cells can grab and destroy targeted cells. Removing that sugar is like replacing a weak magnet with a stronger one: it often boosts the drug’s ability to recruit immune attack, potentially making it more potent, allowing lower doses or clearer clinical advantages, but also adding manufacturing and regulatory considerations investors should watch.

monoclonal antibody medical

"an afucosylated anti-BAFF-R monoclonal antibody"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced its participation in the following upcoming conferences:

• Guggenheim 3rd Annual Healthcare Innovation Conference
  Fireside Chat: Tuesday, November 10, 2026 at 3:00 p.m. ET
  Location: Boston, MA
  
  
• Stifel Healthcare Conference
  Fireside Chat: Wednesday, November 11, 2026 at 10:00 a.m. ET
  Location: New York, NY
  
  
• UBS Global Biopharma Conference
  Fireside Chat: Monday, November 16, 2026 at 12:00 p.m. GMT
  Location: London, UK
  
  
• Jefferies Global Healthcare Conference
  Fireside Chat: Tuesday, November 17, 2026 at 10:30 a.m. GMT
  Location: London, UK

Members of the Jade management team will host one-on-one investor meetings during the conferences.

A live webcast of each of the fireside chats will be available on the Events page of the Jade Biosciences website, with an archived replay accessible for 90 days following the event.

About Jade Biosciences, Inc.

Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an anti-IFN-β monoclonal antibody. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.

Jade Biosciences Contact

Zane Goodwin
IR@JadeBiosciences.com
Media@JadeBiosciences.com